Development of a first in class inhibitor of BET bromodomains and dopamine receptor 2

被引：0
|
作者：
Yoshioka, Makoto
Chauhan, Jay
Fletcher, Steven
Strovel, Jeffrey W.
机构：
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.AM2017-5062
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5062
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Development and pre-clinical assessment of a first-in-class small molecule inhibitor of FLIP
    Higgins, Catherine A.
    Fox, Jennifer
    Majkut, Joanna
    Fiedler, Greti E.
    Roberts, Jamie
    Humphreys, Luke
    Boffey, Ray J.
    Perrior, Trevor R.
    Harrison, Timothy
    Longley, Daniel B.
    CANCER RESEARCH, 2019, 79 (13)
  • [42] Synthesis and Development of a Novel First-in-Class Cofilin Inhibitor for Neuroinflammation in Hemorrhagic Brain Injury
    Alaqel, Saleh, I
    Dlamini, Samkeliso
    Almarghalani, Daniyah A.
    Shettigar, Arjun
    Alhadidi, Qasim
    Kodithuwakku, Sinali H.
    Stary, Creed
    Tillekeratne, L. M. Viranga
    Shah, Zahoor A.
    ACS CHEMICAL NEUROSCIENCE, 2022, 13 (07): : 1014 - 1029
  • [43] CG '806, a First-in-Class Pan-FLT3/BTK Inhibitor, Exhibits Potent Growth Inhibition As a Single Agent and in Combination with a BET Bromodomain Inhibitor or a Bcl2 Inhibitor on Primary AML and CLL Patient Samples
    Kurtz, Stephen E.
    Wilmot, Beth
    Mcweeney, Shannon
    Local, Andrea
    Zhang, Hongying
    Howell, Stephen
    Rice, William
    Druker, Brian J.
    Tyner, Jeffrey W.
    BLOOD, 2017, 130
  • [44] Bupropion: First noradrenaline-dopamine resumption inhibitor approved
    不详
    NERVENARZT, 2007, 78 (06): : 735 - 735
  • [45] Structure-Based Design of a Bromodomain and Extraterminal Domain (BET) Inhibitor Selective for the N-Terminal Bromodomains That Retains an Anti-inflammatory and Antiproliferative Phenotype
    Wellaway, Christopher R.
    Bamborough, Paul
    Bernard, Sharon G.
    Chung, Chun-wa
    Craggs, Peter D.
    Cutler, Leanne
    Demont, Emmanuel H.
    Evans, John P.
    Gordon, Laurie
    Karamshi, Bhumika
    Lewis, Antonia J.
    Lindon, Matthew J.
    Mitchell, Darren J.
    Rioja, Inmaculada
    Soden, Peter E.
    Taylor, Simon
    Watson, Robert J.
    Willis, Rob
    Woolven, James M.
    Wyspianska, Beata S.
    Kerr, William J.
    Prinjha, Rab K.
    JOURNAL OF MEDICINAL CHEMISTRY, 2020, 63 (17) : 9020 - 9044
  • [46] Bromodomains and Extra-Terminal (BET) Inhibitor JQ1 Suppresses Proliferation of Acute Lymphocytic Leukemia by Inhibiting c-Myc-Mediated Glycolysis
    Zhang, Meng-Yi
    Liu, Sheng-Li
    Huang, Wen-Li
    Tang, Da-Bin
    Zheng, Wei-Wei
    Zhou, Neng
    Zhou, Hang
    Abudureheman, Tuersunayi
    Tang, Zhong-Hua
    Zhou, Bin-Bing S.
    Duan, Cai-Wen
    MEDICAL SCIENCE MONITOR, 2020, 26
  • [47] Discovery of a Novel Dopamine D3 Receptor Inhibitor
    Deng Xin-Xian
    Shen Qing
    Xu Li-Li
    Xiong Zi-Jun
    Zhao Wei-Li
    Zhen Xue-Chu
    Fu Wei
    CHEMICAL JOURNAL OF CHINESE UNIVERSITIES-CHINESE, 2011, 32 (08): : 1779 - 1784
  • [48] Preliminary pharmacophore model: Methylphenidate class of dopamine reuptake inhibitor.
    Misra, M
    Gilbert, KM
    Buono, RA
    Venanzi, CA
    Schweri, MM
    Shi, Q
    Deutsch, HM
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2003, 225 : U760 - U760
  • [49] Preliminary pharmacophore model for methylphenidate class of dopamine reuptake inhibitor.
    Venanzi, CA
    Misra, M
    Gilbert, KM
    Buono, RA
    Schweri, MM
    Shi, Q
    Deutsch, HM
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2003, 226 : U448 - U448
  • [50] DOPAMINE-D1 RECEPTOR DEVELOPMENT DEPENDS ON ENDOGENOUS DOPAMINE
    GELBARD, HA
    TEICHER, MH
    BALDESSARINI, RJ
    GALLITANO, A
    MARSH, ER
    ZORC, J
    FAEDDA, G
    DEVELOPMENTAL BRAIN RESEARCH, 1990, 56 (01): : 137 - 140
12345